𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prospective assessment of donor blood screening for antibody to hepatitis B core antigen as a means of preventing posttransfusion non-A, non-B, hepatitis

✍ Scribed by Melchor Hoyos; José V. Sarrión; Teresa Pérez-Castellanos; Martín Prieto; María L. Marty; Vicente Garrigues; Joaquín Berenguer

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
353 KB
Volume
9
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

heart surgery at out institution were prospectively studied. Inclusion crit,eria were the following: absence of transfusion or acute hepatitis during the prior year, alcohol intake <80 gm per day. absence of the use of hepatotoxic drugs, normal aminotransferase values and negative hepatitis B virus (HBV) serological markers. In addition, a prior history of jaundice,

📜 SIMILAR VOLUMES

Prospective assessment of donor blood sc
Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis
✍ S Takano; K Nakamura; S Kawai; O Yokosuka; Y Satomura; M Omata 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

In November 1989, the Japanese Red Cross began transfusion. [4][5][6] In December 1989, first-generation hepscreening blood donors for the hepatitis C virus antiatitis C virus antibodies (anti-HCV) to detect the antibody (anti-HCV) by first-generation assay and high-titer body against nonstructural

Improved serodiagnosis of non-A, non-B h
Improved serodiagnosis of non-A, non-B hepatitis by an assay detecting antibody to hepatitis C virus core antigen
✍ Tohru Katayama; Toshio Mazda; Shu Kikuchi; Shizuko Harada; Yoshiharu Matsuura; J 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 1 views

We examined sequential serum samples from 12 patients with well-characterized posttransfusion non-A, non-B hepatitis who had an acute, resolving self-limited type of clinical course for the presence of antibody to the hepatitis C virus nucleocapsid (core) protein (p22) expressed by a recombinant bac

Clinical value of the guanase screening
Clinical value of the guanase screening test in donor blood for prevention of posttransfusional non-A, non-B hepatitis
✍ Susumu Ito; Yasuhiro Tsuji; Naoyuki Kitagawa; Ishihara Akihiko; Jyoji Syundo; Yo 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB 👁 1 views

We adopted an automated method for measuring guanase in donor blood and examined the incidence of posttransfusional non-A, non-B hepatitis when donor blood with high guanase activities was excluded. Sixtyseven (2.4%) of 2,826 units were excluded from use in transfusion because they had guanase activ

Relationship between guanase activity in
Relationship between guanase activity in donor blood and the incidence of posttransfusional non-A, non-B hepatitis, and a possible method for preventing posttransfusional hepatitis
✍ Susumu Ito; Yasuhiro Tsuji; Akiharu Iwasaki; Naoyuki Kitagawa; Yoshiyuki Tamura; 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB 👁 1 views

A total of 107 recipients, who did not show any evidence of hepatic disorders in pretransfusional liver function tests and gave a negative reaction for HBsAg, were observed from 3 weeks to 3 months after blood transfusion of 71 1 units of blood. The blood was judged suitable for use in transfusion b

Hepatitis B virus prevention strategies
Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen–positive liver donation: A survey of North American, European, and Asian-Pacific transplant programs
✍ Robert Perrillo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

Prophylactic therapy is generally used to prevent reactivated hepatitis B after transplantation of an antibody to hepatitis B core antigen (anti-HBc)-positive liver. To gain insight into current practice, a questionnaire was e-mailed to 89 liver transplant physicians in the United States, Europe, an